About the Authors |
|
xi | |
Prologue: Naked Emperors and Supercomputers |
|
xiii | |
|
1 Population Medicine Versus Personalized Medicine |
|
|
1 | (28) |
|
|
1 | (3) |
|
The Limitations of Population-Based Medicine |
|
|
4 | (1) |
|
Applying the Precision Medicine Model |
|
|
5 | (1) |
|
How Does the Precision Medicine Initiative Fit Into the Equation? |
|
|
6 | (4) |
|
Putting the Precision Medicine Model to Work Now |
|
|
10 | (4) |
|
Understanding the Interlocking Contributors to Disease |
|
|
14 | (2) |
|
The Biological Basis for Personalized Medicine |
|
|
16 | (7) |
|
The Role of the Microbiome |
|
|
23 | (1) |
|
Digital Tools That Enable Precision Medicine |
|
|
24 | (2) |
|
|
26 | (3) |
|
2 Precision Medicine Initiatives and Programs |
|
|
29 | (26) |
|
The US Precision Medicine Initiative |
|
|
30 | (2) |
|
|
32 | (1) |
|
Executing the US Precision Medicine Initiative |
|
|
33 | (2) |
|
What Will the Precision Medicine Initiative Reveal? |
|
|
35 | (2) |
|
The Age of Biomarkers Is Upon Us |
|
|
37 | (3) |
|
Patient Engagement: A Critical Component of Precision Medicine |
|
|
40 | (2) |
|
The Value of Precision Medicine Initiative Data Reaches Beyond the US Precision Medicine Initiative Project |
|
|
42 | (2) |
|
The Role of Electronic Health Record Data |
|
|
44 | (1) |
|
Precision Medicine at Harvard |
|
|
45 | (2) |
|
Precision Medicine at Columbia University |
|
|
47 | (1) |
|
Johns Hopkins Approach to Individualized Care |
|
|
47 | (2) |
|
Mayo Clinic Center for Individualized Medicine |
|
|
49 | (1) |
|
Stanford University Emphasizes Patient Engagement |
|
|
50 | (2) |
|
|
52 | (3) |
|
|
55 | (18) |
|
|
55 | (4) |
|
Putting Genomics to Use in Precision Medicine |
|
|
59 | (2) |
|
Entering the Era of Precision Oncology |
|
|
61 | (4) |
|
Is Cancer a Genetic Disease? |
|
|
65 | (2) |
|
The Value of Pharmacogenomics |
|
|
67 | (1) |
|
The Emerging Science of Nutritional Genomics |
|
|
68 | (2) |
|
|
70 | (3) |
|
4 Small Data, Big Data, and Data Analytics |
|
|
73 | (20) |
|
Understanding the Language of Data Analytics |
|
|
74 | (3) |
|
Algorithms and Machine Learning |
|
|
77 | (1) |
|
Putting Data Analytics to the Test |
|
|
78 | (5) |
|
The Role of Big Data in Hypothesis Testing |
|
|
83 | (4) |
|
Reconciling Big Data and Randomized Controlled Trials |
|
|
87 | (4) |
|
|
91 | (2) |
|
5 How Mobile Technology and EHRs Can Personalize Healthcare |
|
|
93 | (26) |
|
Accessing Patients' "Other" Data |
|
|
93 | (2) |
|
The Role of Mobile Technology in Diabetes Control |
|
|
95 | (4) |
|
The Role of Mobile Technology in Other Diseases |
|
|
99 | (3) |
|
Remote Patient Monitoring |
|
|
102 | (6) |
|
|
108 | (2) |
|
Clinical Decision Support Systems |
|
|
110 | (3) |
|
Star Trek-Like Decision-Making Tools |
|
|
113 | (2) |
|
|
115 | (4) |
|
6 i2b2, SHRINE, Clinical Query, and Other Research Tools |
|
|
119 | (16) |
|
Taking Informatics for Integrating Biology and the Bedside Into New Territory |
|
|
121 | (2) |
|
Shared Health Research Informatics Network Extends the Informatics for Integrating Biology and the Bedside Reach |
|
|
123 | (2) |
|
The Impact of Shared Health Research Information Network on Scientific Research |
|
|
125 | (2) |
|
Beth Israel Deaconess Medicine and Clinical Query 2 |
|
|
127 | (2) |
|
Moving Toward a National Network |
|
|
129 | (2) |
|
Patient-Centered Outcomes Research Initiatives |
|
|
131 | (2) |
|
|
133 | (2) |
|
7 Barriers and Limitations |
|
|
135 | (14) |
|
Does Precision Medicine Cost Too Much? |
|
|
135 | (5) |
|
Filling the Genomics Information Gap |
|
|
140 | (1) |
|
Addressing the Workload Issue |
|
|
141 | (5) |
|
Is There Adequate Scientific Evidence? |
|
|
146 | (1) |
|
Additional Barriers to Surmount |
|
|
147 | (1) |
|
|
147 | (2) |
|
8 Interoperability and Personalized Patient Care |
|
|
149 | (14) |
|
Defining the Basics and Following a Roadmap |
|
|
149 | (2) |
|
What Drives Interoperability? |
|
|
151 | (3) |
|
Policy and Technical Components |
|
|
154 | (2) |
|
Learning From Our Mistakes |
|
|
156 | (2) |
|
Addressing Security Concerns |
|
|
158 | (2) |
|
Understanding the Standards That Facilitate Interoperability |
|
|
160 | (2) |
|
What Outcomes Can Be Expected? |
|
|
162 | (1) |
|
|
162 | (1) |
|
|
163 | (20) |
|
Keeping Patient Data Safe at the Grassroots Level |
|
|
163 | (2) |
|
|
165 | (2) |
|
Additional Health Insurance Portability and Accountability Act Violation Expenses |
|
|
167 | (1) |
|
Calculating the Cost of Security |
|
|
167 | (2) |
|
How Do the HIPAA Regulations Fit In? |
|
|
169 | (3) |
|
Taking the Necessary Preventive Measures |
|
|
172 | (2) |
|
Passwords, Policies, and Procedures |
|
|
174 | (1) |
|
|
175 | (1) |
|
Applying Security Principles to Precision Medicine Initiative |
|
|
176 | (1) |
|
A Case Scenario Requiring Security Protocols |
|
|
177 | (3) |
|
|
180 | (3) |
|
10 Patient and Consumer Engagement |
|
|
183 | (12) |
|
Engaging Responsible Patients |
|
|
184 | (2) |
|
|
186 | (1) |
|
Patient Portals Are Not Enough |
|
|
187 | (1) |
|
|
188 | (2) |
|
Patient-Generated Data and Mobile Engagement |
|
|
190 | (2) |
|
Final Thoughts on the Promise of Precision/Personalized Medicine |
|
|
192 | (1) |
|
|
193 | (2) |
Index |
|
195 | |